Background
Methods
Case definition
Description of the three data sources
The mandatory HIV case reporting (DOVIH)
The ANRS French Perinatal Cohort (ANRS-EPF CO1/CO10/CO11)
The HIV laboratory surveillance (LaboVIH)
Identification of common cases among sources
Imputation of the variable “country of birth” in the source LaboVIH
Capture-recapture estimates
Results
Cross-matches
Capture-recapture estimates
Log-linear models | 95% CI | df | G2
| p | AIC | DIC | ||
---|---|---|---|---|---|---|---|---|
Dependencies between sources | ||||||||
LaboVIH*DOVIH, LaboVIH*EPF, DOVIH*EPF | 126 | 342 | 259,573 | 0 | 0 | 1 | 0 | 0 |
LaboVIH*DOVIH, LaboVIH*EPF | 23 | 239 | 225,263 | 1 | 18.83 | <10-4
| 16.83 | 16.89 |
LaboVIH*DOVIH, DOVIH*EPF | 58 | 274 | 243,331 | 1 | 3.78 | 0.05 | 1.78 | 1.84 |
LaboVIH*EPF, DOVIH*EPF | 153 | 369 | 294,521 | 1 | 0.24 | 0.63 | −1.76 | −1.71 |
LaboVIH*DOVIH, EPF | 29 | 249 | 234,272 | 2 | 18.49 | <10-4
| 14.49 | 14.6 |
LaboVIH*EPF, DOVIH | 51 | 267 | 245,300 | 2 | 30.12 | <10-4
| 26.12 | 26.23 |
DOVIH*EPF, LaboVIH | 85 | 301 | 268,349 | 2 | 5.96 | 0.05 | 1.96 | 2.07 |
LaboVIH, DOVIH, EPF | 49 | 265 | 246,292 | 3 | 30.2 | <10-4
| 24.20 | 24.36 |
Log-linear models | 95% CI () | df | G2
| p | AIC | DIC | |||
---|---|---|---|---|---|---|---|---|---|
Model 1: DO*EPF, LABO*EPF, EPF*place | 154 | 370 | 270 | 469 | 100 | 145,75 | 0,00 | −54,25 | −142,31 |
Model 2: DO*EPF, LABO*EPF, EPF*region | 154 | 370 | 270 | 469 | 100 | 133,74 | 0,01 | −66,26 | −154,32 |
Model 3: DO*EPF, LABO*EPF, EPF*année, Labo*année | 154 | 370 | 270 | 469 | 95 | 141,78 | 0,00 | −48,22 | −131,88 |
Model 4: DO*EPF, LABO*EPF, EPF*place, EPF*region, DO*region | 147 | 363 | 266 | 460 | 97 | 125,12 | 0,03 | −68,88 | −154,30 |
Model 5: DO*EPF, LABO*EPF, EPF*place, EPF*year | 131 | 347 | 260 | 434 | 94 | 132,81 | 0,00 | −55,19 | −137,96 |
Model 6: DO*EPF, LABO*EPF, EPF*region, DO*region, EPF*year | 141 | 357 | 261 | 452 | 96 | 121,31 | 0,02 | −64,69 | −146,59 |
Model 7: DO*EPF, LABO*EPF, DO*place, EPF*place, DO*region, Labo*region, EPF*region, EPF*year | 171 | 387 | 271 | 503 | 93 | 112,72 | 0,07 | −73,28 | −155,17 |
Model 8: DO*EPF, LABO*EPF, DO*place, EPF*place, DO*region, Labo*region, EPF*region | 171 | 387 | 271 | 503 | 96 | 112,48 | 0,05 | −73,52 | −158,06 |
Strata | Total | DOVIH | EPF | LaboVIH | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(95% CI) |
N
obs
| Compl(%) | (95% CI) |
N
obs
| Compl(%) | (95% CI) |
N
obs
| Compl(%) | (95% CI) |
N
obs
| Compl(%) | (95% CI) | ||
Year of diagnosis | ||||||||||||||
2003 | 107 | (72.4;142.7) | 60 | 55.8 | (42.0:82.9) | 30 | 27.9 | (21.0;41.4) | 28 | 26.0 | (19.6:38.7) | 30 | 27.9 | (21.0;41.4) |
2004 | 99 | (68.9;129.4) | 59 | 59.5 | (45.6;85.7) | 35 | 35.3 | (27.0;50.8) | 32 | 32.3 | (24.7;46.5) | 35 | 35.3 | (27.0;50.8) |
2005 | 91 | (62.4;120.9) | 53 | 57.8 | (43.8;85.0) | 27 | 29.5 | (22.3;43.3) | 27 | 29.5 | (22.3;43.3) | 34 | 37.1 | (28.1;54.5) |
2006 | 88 | (55.4;121.8) | 44 | 49.7 | (36.1;79.4) | 18 | 20.3 | (14.8;32.5) | 14 | 15.8 | (11.5;25.3) | 30 | 33.9 | (24.6;54.2) |
Place of birth | ||||||||||||||
France | 152 | (100.3;204.9) | 86 | 56.4 | (42.0;85.7) | 37 | 24.2 | (18.1;36.9) | 47 | 30.8 | (22.9;46.8) | 55 | 36.0 | (26.8;54.8) |
Foreign country | 234 | (158.9;309.9) | 130 | 55.5 | (42.0;81.8) | 73 | 31.1 | (23.6;45.9) | 54 | 23.0 | (17.4;34.0) | 74 | 31.6 | (23.9;46.6) |
Region of diagnosis | ||||||||||||||
Paris area | 198 | (154.7;241.4) | 139 | 70.2 | (57.6;89.9) | 79 | 39.9 | (32.7;51.1) | 79 | 39.9 | (32.7;51.1) | 82 | 41.4 | (34.0;53.0) |
Other regions | 188 | (101.0;276.8) | 77 | 40.8 | (27.8;76.2) | 31 | 16.4 | (11.2;30.7) | 22 | 11.6 | (7.9;21.8) | 47 | 24.9 | (17.0;46.5) |
Total | 387 | (271;503) | 216 | 55.8 | (42.9;79.7) | 110 | 28.4 | (21.9;40.1) | 101 | 26.1 | (20.1;37.3) | 129 | 33.3 | (25.6;47.6) |